1. Anderson DW, Ellenberg JH, Leventhal CM, Reingold SC, Rodriguez M, Silbergerg DH. Revised estimate of the prevalence of multiple sclerosis in the United States. Ann Neurol 1992;31:333-336.

2. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996; 46:907-911.

3. Lumsden C. The neuropathology of multiple sclerosis. In: Vinken P, Bruyn G, eds. Handbook of Clinical Neurology. New York: Elsevier, 1970:217-309.

4. Dawson J. The histology of dissseminated sclerosis. T Roy Soc Edin 1916; 50:517-740.

Hallevorden J, Spatz H. Uber die konzentrische Sklerose und die physikalischchemischen Fakktoren bein der Ausbreitung von Entmarkungsprozessen. Arch Psychiatr Nervenkr 1933; 98:641-701.

Traugott U. Multiple sclerosis: relevance of class I and class II MHC-expressing cells to lesion development. J Neuroimmunol 1983; 16:283-302.

Sobel R, Mitchell M, Fondren G. Intercellular adhesion molecule-1 (ICAM-1) in cellular immune reactions in the human central nervous system. Am J Pathol 1990; 136:1309-1316.

Raine CS, Cannella B, Duijvestijn AM, Cross AH. Homing to central nervous system vasculature by antigen-specific lymphocytes II. Lymphocyte/endothelial cell adhesion during the initial stages of autoimmune demyelination. Lab Invest 1990; 63:476-489. Ozawa K, Suchanek G, Breitschopf H, et al. Patterns of oligodendroglia pathology in multiple sclerosis. Brain 1994; 117:1311-1322.

Bruck W, Porada P, Poser S, et al. Monocyte-macrophage differentiation in early multiple sclerosis lesions. Ann Neurol 1995; 38:788-796.

Grossman RI, Braffman BH, Brorson JR, Goldberg HI, Silberberg DH, Gonzalez-Scarano F. Multiple sclerosis: serial study of gadolinium-enhanced MR imaging. Radiology 1988; 169:117-122.

Miller DH, Rudge P, Johnson G, et al. Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. Brain 1988; 111:927-939.

Gay F, Drye T, Dick G, Asiti N. The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis identification and characterization of primary demyelinating lesion. Brain 1997; 120:1461-1483.

Prineas JW, Kwon EE, Cho ES, et al. Immunopathology of secondary-progressive multiple sclerosis. Ann Neurol 2001; 50(5):646-657.

De Groot CJ, Bergers E, Kamphorst W, et al. Post-mortem MRI-guided sampling of multiple sclerosis brain lesions: increased yield of active demyelinating and (p)reactive lesions. Brain 2001; 124(8):1635-1645.

Navikas V, Link H. Review: cytokines and the pathogenesis of multiple sclerosis. J Neu-rosci Res 1996; 45(4):322-333.

Canella B, Raine CS. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 1995; 37:424-435.

Lucchinetti CF, Brueck W, Rodriguez M, Lassmann H. Multiple sclerosis: lessons from neuropathology. Sem Neurol 1998; 18(3):337-349.

Krogsgaard M, Wucherpfennig KW, Cannella B, et al. Visualization of myelin basic protein (MBP) T-cell epitopes in multiple sclerosis lesions using a monoclonal antibody specific for the human histocompatibility leukocyteantigen (HLA)-DR2-MBP85-99 complex. J Exp Med 2000; 191:1395-1412.

Oksenberg JR, Panzara MA, Bagovich AO, et al. Selection for T-cell recpetor VB-DB-JB gene rearrangements with specificity for a myelin basic protein peptide in MS lesions. Nature 1993; 362:68-70.

Hohlfeld R, Wiendl H. The ups and downs of multiple sclerosis therapeutics. Ann Neurol 2001; 49(3):281-284.

Babbe H, Roers A, Waisman A, et al. Clonal expansion of CD8(+) T-cells dominate the T-cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med 2000; 192:393-404. Sun D, Whitaker JN, Huang Z, et al. Myelin antigen-specific CD8+ T cells are encepha-litogenic and produce severe disease in C57BL/6 mice. J Immunol 2001; 166:7579-7587. Huseby ES, Liggitt D, Brabb T, Schnabel B, Ohlen C, Goverman J. A Pathogenic role for myelin-specific CD8+ T cells in a model for multiple sclerosis. J Exp Med 2001; 194:669-676.

Hoftberger R, Aboul-Enein F, Brueck W, et al. Expression of major histocompatibility complex class I molecules on the different cell types in multiple sclerosis lesions. Brain Pathol 2004; 14:43-50.

26. Neumann H, Medana IM, Bauer J, Lassmann H. Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases. Trends in Neurosci 2002; 25(6):313-319.

27. Bitsch A, Schuchardt J, Bunkowski S, Kuhlmann T, Bruck W. Acute axonal injury in multiple sclerosis correlation with demyelination and inflammation. Brain 2000; 123(Pt 6):1174-1183.

28. Lafaille JJ, Nagashima K, Katsuki M, et al. High incidence of spontaneous autoimmune encephalomyelitis in immunodeficient anti-myelin basic protein T cell receptor transgenic mice. Cell 1994; 78:399-408.

29. Lindert RB, Haase CG, Brehm U, Linington C, Wekerle H, Hohlfeld R. Multiple sclerosis: B- and T-cell responses to the extracellular domain of the myelin oligodendro-cyte glycoprotein. Brain 1999; 122(11):2089-2100.

30. Genain CP, Cannella B, Hauser SL, Raine CS. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med 1999; 5(2):170-175.

31. Reindl M, Linington C, Brehm U, et al. Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study. Brain 1999; 122(Pt 11):2047-2056.

32. Guseo A, Jellinger K. The significance of perivascular infiltrates in multiple sclerosis. J Neurol 1975; 211:51-60.

33. Kerschensteiner M, Gallmeier E, Behrens L, et al. Activated human T cells, B cells and monocytes produce brain-derived neurotrophic factor (BDNF) in vitro and in brain lesions: a neuroprotective role for inflammation? J Exp Med 1999; 189:865-870.

34. Stadelmann C, Kerschensteiner M, Misgeld T, et al. BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune cells and neuronal cells. Brain 2002; 125:75-85.

35. Moalem G, Leibowitz-Amit R, Yoles E, Mor F, Cohen IR, Schwartz M. Autoimmune T cells protect neurons from secondary degeneration after central nervous system axo-tomy. Nat Med 1999; 5(1):49-55.

36. Diemel LT, Copelman CA, Cuzner ML. Macrophages in CNS remyelination: friend or foe? Neurochem Res 1998; 23(3):341-347.

37. Kotter MR, Setzu A, Sim FJ, Van Rooijen N, Franklin RJ. Macrophage depletion impairs oligodendrocyte remyelination following lysolecithin-induced demyelination. Glia 2001; 35(3):204-212.

38. Bitsch A, Kuhlmann T, Da Costa C, Bunkowski S, Polak T, Bruck W. Tumour necrosis factor alpha mRNA expression in early multiple sclerosis lesions: correlation with demyelinating activity and oligodendrocyte pathology. Glia 2000; 29(4):366-375.

39. Pitt D, Werner P, Raine CS. Glutamate excitotoxicity in a model of multiple sclerosis. Nat Med 2000; 6(1):67-70.

40. Selmaj K, Cross AH, Farooq M, Brosnan CF, Raine CS. Non-specific oligodendrocyte cytotoxicity mediated by soluble products of activated T cell lines. J Neuroimmunol 1991; 35:261-271.

41. D'Souza S, Bonetti B, Balasingam V, et al. Multiple sclerosis: fas signaling in oligodendrocyte cell death. J Exp Med 1996; 184:2361-2370.

42. Jurewicz A, Biddison WE, Antel JP. MHC class I-restricted lysis of human oligoden-drocytes by myelin basic protein peptide-specific CD8 T lymphocytes. J Immunol 1998; 160:3056-3059.

43. Merrill JE, Scolding NJ. Mechanisms of damage to myelin and oligodendrocytes and their relevance to disease. Neuropathol Appl Neurobiol 1999; 25(6):435-458.

44. Raine CS, Scheinberg L, Waltz JM. Multiple sclerosis: oligodendrocyte survival and proliferation in an active established lesion. Lab Invest 1981; 45:534-546.

45. Prineas JW, Barnard RO, Kwon EE, Sharer LR, Cho E-S. Multiple sclerosis: remyelination of nascent lesions. Ann Neurol 1993; 33:137-151.

46. Brueck W, Schmied M, Suchanek G, et al. Oligodendrocytes in the early course of multiple sclerosis. Ann Neurol 1994; 35:65-73.

Lucchinetti CF, Brueck W, Rodriguez M, Parisi J, Scheithauer B, Lassmann H. A quantitative study on the fate of the oligodendrocyte in multiple sclerosis lesions: a study of 113 cases. Brain 1999; 122:2279-2295.

Ludwin SK. Oligodendrocyte survival in Wallerian degeneration. Acta Neuropathol 1990; 80:184-191.

Kuhlmann T, Lucchinetti C, Zettl UK, Bitsch A, Lassmann H, Bruck W. Bcl-2-expressing oligodendrocytes in multiple sclerosis lesions. Glia 1999; 28(1):34-39. Prineas JW, Barnard RO, Revesz T, Kwon EE, Sharer L, Cho ES. Multiple sclerosis pathology of recurrent lesions. Brain 1993; 116(Pt 3):681-693.

Wolswijk G. Chronic stage multiple sclerosis lesions contain a relatively quiescent population of oligodendrocyte precursor cells. J Neurosci 1998; 18(2):601-609. Chang A, Tourtellote WW, Rudick R, Trapp BD. Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N Engl J Med 2002; 346(3):165-173. Lucchinetti CF, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; 47:707-717.

Hurst E. Acute haemorrhagic leucoencephalitis: a previous undefined entity. Med J Aust 1941; 2:1-6.

Noseworthy J, Lucchinetti C, Rodriguez M, Weinshenker B. Multiple sclerosis. N Engl Med 2000; 343:938-952.

Lassmann H, Bruck W, Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med 2001; 7(3):115-121. Probert L, Akassoglou K, Pasparakis M, et al. Spontaneous inflammatory demyelina-ting disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor alpha. Proc Natl Acad Sci USA 1995; 92:11294-11298. Griot C, Vandevelde M, Richard A, Peterhans E, Stocker R. Selective degeneration of oligodendrocytes mediated by reactive oxygen species. Free Radical Res Commun 1990; 11(4-5):181-193.

Linington C, Bradl M, Lassmann H, Brunner C, Vass K. Augmentation of demyelina-tion in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am J Pathol 1988; 130: 443-454.

Itoyama Y, Sternberger NH, Webster HD, Quarles RH, Cohen SRR, Richardson EPJ. Immunocytochemical observations on the distribution of myelin-associated glycoprotein and myelin basic protein in multiple sclerosis lesions. Ann Neurol 1980; 7:167-177. Gendelman HE, Pezeshkpour GH, Pressman NJ, et al. A quantitation of myelin-asso-ciated glycoprotein and myelin basic protein loss in different demyelinating diseases. Ann Neurol 1985; 18(3):324-328.

Itoyama Y, Webster HD, Sternberger NH, et al. Distribution of papovavirus, myelin-associated glycoprotein, and myelin basic protein in progressive multifocal leukoence-phalopathy lesions. Neurology 1982; 11(4):396-407.

Rodriguez M. Virus-induced demyelination in mice: ''dying back'' of oligodendrocytes. Mayo Clin Proc 1985; 60:433-438.

Rodriguez M, Sheithauer B. Ultrastructure of multiple sclerosis. Ultrastruct Pathol 1994; 18:3-13.

Ludwin S, Johnson E. Evidence of a ''dying back'' gliopathy in demyelinating disease. Ann Neurol 1981:301-305.

Aboul-Enein F, Rauschka H, Kornek B, et al. Preferential loss of myelin-associated glycoprotein reflects hypoxia-like white matter damage in stroke and inflammatory brain diseases. J Neuropath Exp Neurol 2003; 62(1):25-33.

Lassmann H. Hypoxia-like tissue injury as a component of multiple sclerosis lesions. J Neurol Sci 2003; 206(2):187-191.

68. Graumann U, Reynolds R, Steck AJ, Schaeren-Wiemers N. Molecular changes in normal appearing white matter in multiple sclerosis are characteristic of neuroprotective mechanisms against hypoxic insult. Brain Pathol 2003; 13(4):554-573.

69. Mahad DJ, Trebst C, Kivisakk P, et al. Expression of chemokine receptors CCR1 and CCR5 reflects differential activation of mononuclear phagocytes in pattern II and pattern III multiple sclerosis lesions. J Neuropath Exp Neurol 2004; 63(3):262-273.

70. Lucchinetti CF, Bruck W, Lassmann H. Evidence for pathogenic heterogeneity in multiple sclerosis. Ann Neurol 2004; 56:308.

71. Barnett MH, Prineas JW. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol 2004; 55(4):458-468.

72. Barnett MH, Prineas JW. Pathological heterogeneity in multiple sclerosis: a reflection of lesion stage? Ann Neurol 2004; 56(2):309.

73. Pittock SJ, McClelland RL, Achenbach SJ, Konig F, et al. Clinical course, pathological correlations, and outcome of biopsy proven inflammatory demyelinating disease. J Neurol Neurosurg Psychiatry 2005; 76(12):1693-1697.

74. Keegan M, Konig F, McClelland R, Bruck W, et al. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 2005; 366: 579-582.

75. Lucchinetti CF, Altintas A, Wegner C, Erickson BJ, Lassmann H, Bruck W. Magnetic resonance imaging correlates of multiple sclerosis pathologic subtypes. Ann Neurol 2003; 54(suppl 7):67.

76. Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 2003; 61:1528-1532.

77. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology 2001; 56(11):1496-1504.

78. Cohen JA, Cutter GR, Fischer JS, et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 2002; 59(5):679-687.

79. European Study Group on Intereron b-1b in Secondary Progressive MS. Placebo-controlled multicentre randomized trial of interferon b-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352:1491-1497.

80. North American Study Group on Interferon beta-1b in secondary progressive MS: results from a three year controlled study. Neurology 2004; 63:1788-1795.

81. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000; 343:1430-1438.

82. Pittock SJ, Mayr WT, McClelland RL, et al. Change in MS-related disability in a population-based cohort—A 10-year follow-up study. Neurology 2004; 62(1):51-59.

83. Berger JR, Sheremata WA, Resnick L, Atherton S, Fletcher MA, Norenberg M. Multiple sclerosis-like illness occurring with human immunodeficiency virus infection. Neurology 1989; 39:324-329.

84. Coles AJ, Wing MG, Molyneux P, et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 1999; 46(3):296-304.

85. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon ß-1b in the treatment of MS: final outcome of the randomized controlled trial. Neurology 1995; 45:1277-1285.

86. Molyneux PD, Kappos L, Polman C, et al. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis. The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. Brain 2000; 123(Pt 11):2256-2263.

87. Barnes D, Munro PM, Youl BD, Prineas JW, McDonald WI. The longstanding MS lesion A quantitative MRI and electron microscopic study. Brain 1991; 114: 1271-1280.

Truyen L, van Waesberghe JH, van Walderveen MA, et al. Accumulation of hypo-intense lesions (''black holes'') on T1 spin-echo MRI correlates with disease progression in multiple sclerosis. Neurology 1996; 47(6):1469-1476.

van Walderveen MA, Kamphorst W, Scheltens P, et al. Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology 1998; 50:1282-1288.

van Waesberghe J, Kamphorst W, De Groot C, et al. Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol 1999; 46:747-754.

Bruck W, Bitsch A, Kolenda H, Bruck Y, Stiefel M, Lassmann H. Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol 1997; 42(5):783-793.

Bjartmar C, Kidd G, Mork S, Rudick R, Trapp BD. Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann Neurol 2000; 48(6):893-901.

Losseff N, Wang L, Lai H, Yoo D, Gwane-Cain M, McDonald W. Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain 1996; 119:2009-2019. Thompson AJ, Polman CH, Miller DH, et al. Primary progressive multiple sclerosis. Brain 1997; 120:1085-1096.

Davie CA, Barker GJ, Thompson AJ, Tofts PS, McDonald WI, Miller DH. 1H magnetic resonance spectroscopy of chronic cerebral white matter lesions and normal appearing white matter in multiple sclerosis. J Neurol Neurosurg Psychiatry 1997; 63:736-742.

Suhy J, Rooney WD, Goodkin DE. 1H MRSI comparison of white matter and lesions in primary progressive and relapsing-remitting multiple sclerosis. Mult Scler 2000; 6:148-155.

Tortorella C, Viti B, Bozzali M. A magnetization trasfer histogram study of normal appearing brain tissue in MS. Neurology 2000; 54:186-193.

Evangelou N. Regional axonal loss in the corpus callosum correlates with cerebral white matter lesion volume and distribution in multiple sclerosis. Brain 2003; 123:1845-1849. Lovas G, Szilagyi N, Majtenyi K, Palkovits M, Komoly S. Axonal changes in chronic demyelinated cervical spinal cord plaques. Brain 2000; 123(Pt 2):308-317. Pelletier D, Nelson SJ, Oh J, et al. MRI lesion volume heterogeneity in primary progressive MS in relation with axonal damage and brain atrophy. J Neurol Neurosurg Psychiatry 2003; 74:950-952.

Rovaris M, Bozzali M, Santuccio G, et al. In vivo assessment of the brain and cervical cord pathology of patients with primary progressive multiple sclerosis. Brain 2001; 124:2540-2549.

Rocca MA, Iannucci G, Rovaris M, Comi G, Filippi M. Occult tissue damage in patients with primary progressive multiple sclerosis is independent of T2-visible lesions—a diffusion tensor MR study. J Neurol 2003; 250:456-460.

Rivera-Quinones C, McGavern D, Schmelzer JD, Hunter SF, Low PA, Rodriguez M. Absence of neurological deficits following extensive demyelination in a class I-deficient murine model of multiple sclerosis. Nat Med 1998; 4(2):187-193. Murray P, McGavern D, Lin X, et al. Perforin-dependent neurologic injury in a viral model of multiple sclerosis. J Neurosci 1998; 18:7306-7314.

Kornek B, Lassmann H. Axonal pathology in multiple sclerosis: a historical note. Brain Pathol 1999; 9:651-656.

Kornek B, Storch MK, Weissert R, et al. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol 2000; 157(1):267-276.

Ferguson B, Matyszak MK, Esiri MM, Petty VH. Axonal damage in acute multiple sclerosis lesions. Brain 1997; 120:393-399.

108. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338:278-285.

109. Smith KJ, Kapoor R, Hall SM, Davies M. Electrically active axons degenerate when exposed to nitric oxide. Ann Neurol 2001; 49(4):470-476.

110. Sadatipour BT, Greer JM, Pender MP. Increased circulating antiganglioside antibodies in primary and secondary progressive multiple sclerosis. Ann Neurol 1998; 44:980-983.

111. Neumann H. Molecular mechanisms of axonal damage in inflammatory central nervous system diseases. Curr Opin Neurol 2003; 16(3):267-273.

112. Sadahiro S, Yoshikawa H, Yagi N, et al. Morphometric analysis of the myelin-associated oligodendrocytic basic protein-deficient mouse reveals a possible role for mye-lin-associated oligodendrocytic basic protein in regulating axonal diameter. Neuroscience 2000; 98(2):361-367.

113. Yoshikawa H. Myelin-associated oligodendrocytic basic protein modulates the arrangement of radial growth of the axon and the radial component of myelin. Medi Electron Microsc 2001; 34(3):160-164.

114. Lassmann H. Axonal injury in multiple sclerosis. J Neu Neurosurg Psychiatry 2003; 74:695-697.

115. Lucchinetti C, Bruck W. The pathology of primary progressive multiple sclerosis. Mult Scler 2004; 10(suppl 1):S23-S30.

116. Cifelli A, Arridge M, Jezzard P, Esiri MM, Palace J, Matthews PM. Thalamic neurodegeneration in multiple sclerosis. Ann Neurol 2002; 52(5):650-653.

117. Kidd D, Barkhof F, McConnell R, Algra PR, Allen IV, Revesz T. Cortical lesions in multiple sclerosis. Brain 1999; 122(1):17-26.

118. Peterson JW, Bo L, Mork S, Chang A, Trapp BD. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 2001; 50(3):389-400.

119. Bo L, Vedeler C, Nyland H, Trapp B, Mork S. Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration. Mult Scler 2003; 9(4): 323-331.

120. Bo L, Vedeler C, Nyland H, Trapp B, Mork S. Subpial demyelination in the cerebral cortex of multiple sclerosis patients. J Neuropathol Exp Neurol 2003; 62(7):723-732.

121. Bozzali M, Cercignani M, Sormani MP, Comi G, Filippi M. Quantification of brain gray matter damage in different MS phenotypes by use of diffusion tensor MR Imaging. AJNR 2002; 23:985-988.

122. Kutzelnigg A, Lucchinetti CF, Stadelmonn C, et al. Cortical demelination and diffuse white matter injury in multiple sclerosis. Brain 2005; 128(11):2705-2712.

123. Ingle GT, Stevenson VL, Miller DH, Thompson AJ. Primary progressive multiple sclerosis: a 5-year clinical and MR study. Brain 2003; 126:2528-2536.

124. Kidd D, Thorpe JW, Kendall BE, et al. MRI dynamics of brain and spinal cord in progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 1996; 69:15-19.

125. Kidd D, Thorpe JW, Thompson AJ, et al. Spinal cord MRI using multi-array coils and fast spin echo. II. Findings in multiple sclerosis. Neurology 1993; 43:2632-2637.

126. Filippi M, Campi A, Dousset V, et al. A magnetization transfer imaging study of normal-appearing white matter in multiple sclerosis. Neurology 1995; 45:478-482.

127. Filippi M, Rocca M, Martino G, Horsfield M, Comi G. Magnetization transfer changes in the normal appearing white matter precede the appearance of enhancing lesions in patients with multiple sclerosis. Ann Neurol 1998; 43:809-814.

128. Ciccarelli O, Werring DJ, Wheeler-Kingshott CA, et al. Investigation of MS normal-appearing brain using diffusion tensor MRI with clinical correlations. Neurology 2001; 56:926-933.

129. Dehmeshki J, Chard DT, Leary SM, et al. The normal appearing grey matter in primary progressive multiple sclerosis: a magnetisation transfer imaging study. J Neurol 2003; 250:67-74.

Rovaris M, Bozzali M, Iannucci G, et al. Assessment of normal-appearing white and gray matter in patients with primary progressive multiple sclerosis: a diffusion-tensor magnetic resonance imaging study. Arch Neurol 2002; 59:1406-1412. Allen I, McKeown S. A histological, histochemical and biochemical study of the macro-scopically normal white matter in multiple sclerosis. J Neurosci 1979; 41:81-91. Allen IV, Glover G, Anderson R. Abnormalities in the macroscopically normal white matter in cases of mild or spinal multiple sclerosis. Acta Neuropathol 1981; 1981(suppl 7): 176-181.

Allen IV, McQuaid S, Mirakhur M, Nevin G. Pathological abnormalities in the normal-appearing white matter in multiple sclerosis. Neurol Sci 2001; 22(2):141-144. McKeown SR, Allen V. The cellular origin of lysosomal enzymes in the plaque of multiple sclerosis: a combined histological and biochemical study. Neuropath Appl Neuro-biol 1978; 4:471-482.

Evangelou N, Esiri MM, Smith S, Palace J, Matthews PM. Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis. Ann Neurol 2000; 47(3):391-395.

Thompson AJ, Kermode AG, Wicks D, et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 1991; 29:53-62. Weinshenker BG, Lucchinetti CF. Acute leukoencephalopathies: differential diagnosis and investigation. Neurologist 1998; 4:148-166.

Marburg O. Die sogenannte ''akute Multiple Sklerose''. J Psychiatric Neurol 1906; 27:211-312.

Wood DD, Bilbao JM, O'Connors P, Moscarello MA. Acute multiple sclerosis (Marburg type) is associated with developmentally immature myelin basic protein. Ann Neurol 1996; 40(1):18-24.

Storch MK, Piddlesden S, Haltia M, Livanainen M, Morgan P, Lassmann H. Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination. Ann Neurol 1998; 43(4):465-471.

Courville C. Concentric sclerosis. In: Bruyn PVaG, ed. Handbook of Clinical Neurology. Amsterdam: Elsevier, 1970:437-451.

Kuroiwa Y. Clinical and epidemiological aspects of multiple sclerosis in Japan. Jap J Med 1982; 21(2):135-140.

Korte J, Born E, Vos L, Breuer T, Wondergem J. Balo concentric sclerosis: MR diagnosis. AJNR 1994; 15:1284-1285.

Revel M, Valiente E, Gray F, Beges C, Degos J, Brugieres P. Concentric MR patterns in multiple sclerosis Report of two cases. J Neuroradiol 1993; 20(4):252-257.

Chen C, Ro L, Chang C, Ho Y, Lu C. Serial MRI studies in pathologically verified

Balo's concentric sclerosis. J Comput Assist Tomogr 1996; 20:732-735.

Garbern J, Spence A, Alvord E. Balo's concentric demyelination diagnosed premortem.

Neurology 1986; 36:1610-1614.

Gharagozloo A, Poe L, Collins G. Antemortem diagnosis of Balo concentric sclerosis: correlative MR imaging and pathologic features. Radiology 1994; 191:817-819. Hanemann C, Kleinschmidt A, Reifenberger G, Freud H, Seitz R. Balo concentric sclerosis followed by MRI and positron emission tomography. Neuroradiol 1993; 35:578-580.

Karaarslan E, Altintas A, Senol U, et al. Balo's concentric sclerosis: clinical and radiologic features of five cases. Am J Neuroradiol 2001; 22(7):1362-1367. Spiegel M, Kruger H, Hofmann E, Kappos L. MRI study of Balo's concentric sclerosis before and after immunosuppressant therapy. J Neurol 1989; 236(8):487-488. Stadelmann C, Ludwin SK, Tabira T, et al. Tissue preconditioning may explain concentric lesions in Balo's type of multiple sclerosis. Brain 2004; 128: 979-987. Wingerchuk DM. Postinfectious encephalomyelitis. Curr Neurol Neurosci Rep 2003; 3(3):256-264.

153. Kepes J. Large focal tumor-like demyelinating lesions of the brain: intermediate entity between multiple sclerosis and acute disseminated encephalomyelitis: A study of 31 patients. Ann Neurol 1993; 33:18-27.

154. Masdeu JC, Moreira J, Trasi S, Visintainer P, Cavaliere R, Grundman M. The open ring A new imaging sign in demyelinating disease. J Neuroimaging 1996; 6:104-107.

155. Lucchinetti CF, Mandler RN, McGavern D, et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002; 125(Pt 7):1450-1461.

156. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999; 53(5):1107-1114.

157. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364:2106-2112.

158. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optico-spinal multiple sclerosis binds to the aquaporin-4 water channel. JEM 2005; 202:473-477.

159. Whitney LW, Ludwin SL, McFarland HF, Biddison WE. Microarray analysisof gene expression in mutliple sclerosis and EAE identifies 5-lipoxygenase as a component of inflammatory lesions. J Neuroimmunol 2001; 121:40-48.

160. Lock C, Hermans G, Pedotti R, et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 2002; 8:500-508.

161. Mycko MP, Papoian R, Boschert U, Raine CS, Selmaj KW. cDNA microarray analysis in multiple sclerosis lesions: detection of genes associated with disease activity. Brain 2003; 126:1048-1057.

162. Chabas D, Baranzini SE, Mitchell O, et al. The influence of the proinflammatory cyto-kine, osteopontin, on autoimmune demyelinating disease. Science 2001; 294:1731-1735.

163. Lucchinetti CF, Parisi J, Bruck W. The pathology of multiple sclerosis. Neurol Clin 2005; 23(1):77-105.

164. Cox A, Coles A, Nagui A, et al. A case of Neuromyelitis optica. Lancet Neurology 2005; 4:510-515.

0 0

Post a comment